Bristol-myers Squibb Compnay

Jin-Hua Sun

Julie A Lemm

Nicholas A Meanwell

John F Kadow

Piyasena Hewawasam

Makonen Belema

Omar D Lopez

Alan Xiangdong Wang

Yong Tu

Ningning Xu

Samayamunthula Venkata Satya Arun Kumar Gupta

Ying-Kai Wang

Pothukanuri Srinivasu

Robert A Fridell

Donald R O'Boyle, Ii

Donald R O'Boyle

Ponugupati Suresh Kumar

Indasi Gopi Kumar

Chunfu Wang

Peter Nower

Karen Rigat

Donald R O'BOYLE Ii

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

The present invention includes an assay useful for identifying inhibitors of Hepatitis C virus (HCV) activity. Particularly, the present invention is directed to a dual HCV assay useful for high throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and the amount of cytotoxicity associated with that test compound. The present invention also includes compounds discovered using this assay, compositions containing such compounds and methods of treating Hepatitis C by the administration of such compounds. The present invention also includes reporter assays using enzymes associated with HCV RNA replication, as well as a cell line having ATTC Accession No. PTA-4583.

Hepatitis C virus assays

Growing community of inventors

North Haven, CT, United States of America

Jin-Hua Sun